Literature DB >> 15275582

Immunity in theileriosis.

A D Irvin1.   

Abstract

The theilerioses can be separated on the basis of their principal pathogenic features, into a lymphoproliferative group caused by Theileria parva and T. annulata in cattle, and T. hirci in goats and sheep, and a haemoproliferative group caused by T. sergenti and T. mutans both in cattle. In the former group, proliferation of parasites within lymphoid cells followed by lymphodestruction are the main pathogenic features; whereas in the latter group, invasion and destruction of erythrocytes, causing anaemia, are more important. In addition, a number of other theilerial parasites which cause mild or inapparent infections, are found in domestic livestock. This review focuses on T. parva, the causative agent of East Coast fever (ECF) in cattle in East and Central Africa, because it is the most pathogenic species and the immunology of ECF has been more intensively studied than that of the other theilerioses.

Entities:  

Year:  1985        PMID: 15275582     DOI: 10.1016/0169-4758(85)90056-0

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  3 in total

1.  Identification of different Theileria species (Theileria lestoquardi, Theileria ovis, and Theileria annulata) in naturally infected sheep using nested PCR-RFLP.

Authors:  Mahdieh Zaeemi; Hamidreza Haddadzadeh; Parvaneh Khazraiinia; Bahram Kazemi; M Bandehpour
Journal:  Parasitol Res       Date:  2010-10-27       Impact factor: 2.289

2.  The effects of drugs on the formation of Theileria annulata merozoites in vitro.

Authors:  F M Fritsch; H Mehlhorn; E Schein; M Hauser
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

3.  Hematological Changes Associated with Theileria orientalis Infection in Korean Indigenous Cattle.

Authors:  Suhee Kim; Do-Hyeon Yu; Sung-Woo Kang; Jeong-Byoung Chae; Kyoung-Seong Choi; Hyeon-Cheol Kim; Bae-Keun Park; Joon-Seok Chae; Jinho Park
Journal:  Korean J Parasitol       Date:  2017-10-31       Impact factor: 1.341

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.